Daniel Barber - Sep 26, 2025 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Signature
/s/ Lori Braender, as Attorney-In-Fact
Stock symbol
AQST
Transactions as of
Sep 26, 2025
Transactions value $
-$551,191
Form type
4
Date filed
9/29/2025, 04:26 PM
Previous filing
Sep 22, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Barber Daniel President and CEO, Director C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN /s/ Lori Braender, as Attorney-In-Fact 2025-09-29 0001742266

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AQST Common Stock Sale -$551K -91.3K -9% $6.03 923K Sep 26, 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4.
F2 The reported transaction involves sale transactions from $6.00 to $6.11 per share. The weighted average price per share was $6.0343. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price.